Navigation Links
The Quigley Corporation Reports First Quarter 2009 Results
Date:5/1/2009

rvations obtained from the study relate to positive effect on nerve functioning, the Company may, in the future, be focusing on a broader therapeutic area.

The World Health Organization estimates, more than 171 million people have diabetes worldwide. It is also estimated that 20 million people, representing approximately 7% of the United States population have diabetes of which some 60% will suffer from mild to severe nerve damage due to Diabetic Peripheral Neuropathy. Conditions associated with Diabetic Peripheral Neuropathy include numbness, skin ulcers, constant pain or extreme sensitivity to stimulus.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will allow this Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration.

Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound; referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well-controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufactur
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
2. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
3. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
4. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
5. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
6. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
7. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
8. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
9. Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes
10. Protein Sciences Corporation Appoints New Board of Directors
11. Digirad Corporation Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Camp Soaring Eagle today announced it ... Cornville, AZ. The nonprofit organization, founded in July ... to attend medically supervised camps at no cost ... a variety of programs to Arizona families and ... illnesses including: Illness Specific Camping Weekends, Illness Specific ...
(Date:7/28/2014)... WI (PRWEB) July 28, 2014 Quincy ... Prevagen® , is pleased to announce the release of ... by company president and co-founder Mark Underwood. , The ... health information, offering useful techniques for readers to improve ... as an unavoidable conclusion, The Brain Health Guide provides ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... know it takes humans just milliseconds to look at someone,s ... a new study finds that certain facial features seem to ... The shape and size of the mouth, for example, appear ... are keys to attractiveness. The study findings suggest ...
(Date:7/28/2014)... Ticket Down is reliable source for ... TX at the Cotton Bowl. The 2014 Guinness International ... it is an eight team tourney. The tournament participants ... from La Liga, Serie A, English Premier League, and Superleague ... on the pitch include: Manchester United, Manchester City, Olympiacos, ...
(Date:7/28/2014)... Glutamine is the most abundant single ... be conditionally essential during times when the body undergoes ... & Immune System Support. , Having a heavy work ... supplementing with additional glutamine may be advantageous. Glutamine supplementation ... body, digestion and immune system function. Stress on the ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... ADHD who carry a specific type of dopamine ... (MPH) than those without the genotype, according to ... The findings come from the first-ever placebo-controlled ... school age children to evaluate variants of the ...
... took the banned substance were leaner and ran faster, ... hormone, a substance frequently implicated in sports doping scandals, ... shows. , Australian researchers gave 96 non-professional athletes aged ... saline placebo. Participants included 63 men and 33 women. ...
... NEW ORLEANS, LA (May 3, 2010) Researchers have ... bowel disease, while other science shows that intra-abdominal fat ... patients, and new technology shows promising results for improvements ... the studies being presented at Digestive Disease Week (DDW) ...
... 2010) The results of new research results published ... the American College of Surgeons show that a ... hospital surgical ward. Postoperative pneumonia is a ... most common infectious complication after urinary tract and wound ...
... and without symptoms, screening mammography may be inappropriate, researchers say ... under the age of 40 result in many return visits ... a new study finds. , Almost 30 percent of ... getting mammograms, although they,re not generally recommended until age 40. ...
... later outcomes, studies show , MONDAY, May 3 (HealthDay ... critical prenatal, maternal and environmental factors can be in shaping ... things, the studies found that kids who stayed glued to ... who smoked or took antidepressants during pregnancy had raised risks ...
Cached Medicine News:Health News:Research helps end guesswork in prescribing ADHD drug 2Health News:Human Growth Hormone Does Boost Athletic Performance 2Health News:Human Growth Hormone Does Boost Athletic Performance 3Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 2Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 3Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 4Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 5Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 6Health News:Surgeons' pilot prevention program reduces incidence of postoperative pneumonia 2Health News:Effects of TV, Drug Exposures in Early Life May Be Long-Lasting 2Health News:Effects of TV, Drug Exposures in Early Life May Be Long-Lasting 3
(Date:7/28/2014)... 2014 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... of the KB001-A development program, including an update on ... KB001-A Collaboration Update KaloBios announced that ... regain all rights to KaloBios, KB001-A program. Under this ... 2010 has been terminated. Under that collaboration agreement, Sanofi ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
(Date:7/28/2014)... Colo. , July 28, 2014  Array ... financial results for the fourth quarter and ... a conference call to discuss those results ... Chief Executive Officer and Michael Carruthers ... call.Conference Call InformationDate:Tuesday, August 12, 2014Time:9:00 a.m. ...
Breaking Medicine Technology:KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... -First Combination Study of a MET and EGFR Inhibitor-, ... (Nasdaq: EXEL ) today announced that it has ... non-small cell lung cancer (NSCLC) who have had,progressive disease ... a small molecule that simultaneously inhibits the MET, RET ...
... ASHBURN, Va., Jan. 4 Innocoll, Inc., ... first of a series of,planned phase 2 ... subsidiary,Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE ... has commenced dosing., Innocoll,s BUPIVACAINE SURGICAL ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4
... ORTHOSTAR table is the most ... It was designed for both ... traction with an integrated shoulder ... special purpose operating table for ...
... theatre is ready for all current and future ... design allows a quick, problem-free conversion to meet ... connected securely and sturdily to MARS through a ... should ever be a problem in spite of ...
... Exclusive, 210° Top Rotation provides ... purpose surgery. The Hercules 6700B eliminates ... during head-end procedures, while providing ample ... to sit during procedures. Removable back ...
... schaereraxis 200/300 product range includes ... been designed for the varied ... in the surgical practice, in ... A favorable price-performance ratio takes ...
Medicine Products: